Component

PI3K-sensitive glucose response in mouse C2C12 cells

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Pharmacological experiments implicated PI3K, while mTOR inhibition did not account for the isoleucine glucose-uptake response.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Mouse C2C12 myotubes; pathway inhibitor experiments.
    limitations
    Inhibitor evidence does not establish direct binding of isoleucine to PI3K or identify the upstream sensor.
    nutrient_topic
    L-Isoleucine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Isoleucine
    plain_language
    This effect was not simply the familiar mTOR protein-growth pathway.
    primary_references
    Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes. · 2003 · https://pubmed.ncbi.nlm.nih.gov/14651987/ · DOI 10.1016/j.bbrc.2003.11.039

    L-Isoleucine: transport, translation, catabolism and cross-nutrient mechanisms (2026-09-19) · lines 354–360

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Mouse C2C12 myotubes; pathway inhibitor experiments. · source_derived_draft · unverified_draft

    ## isoleucine-myotube-pi3k This effect was not simply the familiar mTOR protein-growth pathway. Pharmacological experiments implicated PI3K, while mTOR inhibition did not account for the isoleucine glucose-uptake response. Model: Mouse C2C12 myotubes; pathway inhibitor experiments. Limitations: Inhibitor evidence does not establish direct binding of isoleucine to PI3K or identify the upstream sensor. Evidence access: Primary abstract Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes. · 2003 · https://pubmed.ncbi.nlm.nih.gov/14651987/ · DOI 10.1016/j.bbrc.2003.11.039
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards